Shares of American pharmaceutical and biotechnology company Moderna, Inc. (NASDAQ: MRNA) rose 9.3% to close at $233.70 on Monday after the company provided updates on its mRNA pipeline.  Moderna is currently working on 40 development programs, including 23 ongoing clinical studies encompassing mRNA infectious disease vaccines and mRNA therapeutics spanning seven different modalities. CEO Comments  The CEO of Moderna, Stephane Bancel, said, "2021 was a year of incredible impact and growth for Moderna. Because of our many years of investment in mRNA technology we were ready to develop and launch our Covid-19 vaccine which helped millions of people around the world.
https://www.tipranks.com/news/moderna-provides-covid-19-vaccine-update-shares-jump-9?utm_source=advfn.com&utm_medium=referral
Moderna (NASDAQ:MRNA)
Gráfico Histórico do Ativo
De Abr 2022 até Mai 2022 Click aqui para mais gráficos Moderna.
Moderna (NASDAQ:MRNA)
Gráfico Histórico do Ativo
De Mai 2021 até Mai 2022 Click aqui para mais gráficos Moderna.